Shravan Shetty, Managing Director, Primus Partners, shared his view that Sudeep Pharma is commanding a premium due to steady revenue growth over the last three years and strong mid-20s EBITDA margins, which are higher than many peers in the specialty pharma-ingredients space. He also highlights that with a customer base across 70 countries and exports forming a significant share of revenues, the company benefits from strong product and geographic diversification.